Status:
UNKNOWN
The Efficacy of Oral Probiotics on Neonatal Hyperbilirubinemia
Lead Sponsor:
China Medical University Hospital
Conditions:
Hyperbilirubinemia, Neonatal
Eligibility:
All Genders
Phase:
NA
Brief Summary
This trial will be carried out in two stages in the sick baby room of the Children's Hospital of China Medical University (CMUH). The first stage is: the enzyme active reaction kit (usually called API...
Detailed Description
Hyperbilirubinemia is one of the common diseases in neonates. According to the literature, the incidence of neonatal jaundice is around 60\~70% in Western countries, and even higher among newborns of ...
Eligibility Criteria
Inclusion
- Full-term infants (≧37 weeks).
- Jaundice index greater than 15 mg/dl on the fourth day after birth.
Exclusion
- Hypothyroidism
- Trisomy 21
- Maternal blood type A, B and O incompatibility
- Gastrointestinal disease
- Glucose-6-Phosphate Dehydrogenase deficiency (G6PD deficiency)
- Hemangioma
- Cephalhaematoma or hemorrhages
- Severe asphyxia (stage III)
- Fetal chromosomal anomalies
- Cyanotic congenital heart disease
- Omphalocele
- Early onset sepsis
- Liver failure
Key Trial Info
Start Date :
May 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03876678
Start Date
May 24 2019
End Date
December 31 2023
Last Update
July 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, 40447